Ken Griffin Gritstone Bio, Inc. Transaction History

Citadel Advisors LLC

$483 Billion
Q2 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Gritstone Bio, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 34,600 shares of GRTS stock, worth $19,030. This represents 0.0% of its overall portfolio holdings.

Number of Shares

34,600

Previous 173,300 80.03%

Holding current value

$19,030

Previous $445,000 95.28%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$0.62 - $2.35 $59,772 - $226,556	-96,407 Reduced 58.72%	67,786 $42,000
Q1 2024 May 15, 2024	SELL	$1.96 - $2.9 $275,142 - $407,099	-140,379 Reduced 46.09%	164,193 $421,000
Q4 2023 Feb 14, 2024	SELL	$1.28 - $2.85 $61,653 - $137,275	-48,167 Reduced 13.66%	304,572 $621,000
Q3 2023 Nov 14, 2023	SELL	$1.19 - $2.26 $104,254 - $197,996	-87,609 Reduced 19.9%	352,739 $606,000
Q2 2023 Aug 14, 2023	SELL	$1.66 - $3.03 $194,912 - $355,773	-117,417 Reduced 21.05%	440,348 $858,000
Q1 2023 May 15, 2023	BUY	$2.13 - $3.74 $361,993 - $635,613	169,950 Added 43.82%	557,765 $1.55 Million
Q4 2022 Feb 14, 2023	SELL	$2.17 - $3.92 $125,415 - $226,556	-57,795 Reduced 12.97%	387,815 $1.34 Million
Q3 2022 Nov 14, 2022	SELL	$2.46 - $4.75 $146,067 - $282,040	-59,377 Reduced 11.76%	445,610 $1.15 Million
Q2 2022 Aug 15, 2022	SELL	$1.77 - $4.34 $238,080 - $583,769	-134,509 Reduced 21.03%	504,987 $1.22 Million
Q1 2022 May 16, 2022	BUY	$4.03 - $12.19 $1.18 Million - $3.56 Million	292,415 Added 84.25%	639,496 $2.64 Million
Q4 2021 Feb 14, 2022	BUY	$8.76 - $13.71 $1.17 Million - $1.84 Million	133,961 Added 62.86%	347,081 $4.46 Million
Q3 2021 Nov 15, 2021	BUY	$6.41 - $13.54 $1.15 Million - $2.43 Million	179,619 Added 536.16%	213,120 $2.3 Million
Q2 2021 Aug 16, 2021	SELL	$8.13 - $10.2 $3.39 Million - $4.25 Million	-416,695 Reduced 92.56%	33,501 $305,000
Q1 2021 May 17, 2021	BUY	$4.07 - $27.11 $1.83 Million - $12.2 Million	450,196 New	450,196 $4.25 Million
Q3 2020 Nov 16, 2020	SELL	$2.63 - $8.09 $204,482 - $628,997	-77,750 Closed	0 $0
Q2 2020 Aug 14, 2020	SELL	$5.69 - $8.17 $131,268 - $188,481	-23,070 Reduced 22.88%	77,750 $517,000
Q1 2020 May 15, 2020	BUY	$5.47 - $11.3 $31,282 - $64,624	5,719 Added 6.01%	100,820 $587,000
Q4 2019 Feb 14, 2020	BUY	$7.07 - $11.61 $33,405 - $54,857	4,725 Added 5.23%	95,101 $853,000
Q3 2019 Nov 14, 2019	SELL	$8.45 - $12.28 $480,297 - $697,995	-56,840 Reduced 38.61%	90,376 $780,000
Q2 2019 Aug 14, 2019	BUY	$9.2 - $15.7 $684,434 - $1.17 Million	74,395 Added 102.16%	147,216 $1.64 Million
Q1 2019 May 15, 2019	BUY	$9.97 - $18.96 $602,686 - $1.15 Million	60,450 Added 488.64%	72,821 $0
Q4 2018 Feb 14, 2019	SELL	$11.61 - $31.1 $602,965 - $1.62 Million	-51,935 Reduced 80.76%	12,371 $191,000
Q3 2018 Nov 13, 2018	BUY	$14.24 - $14.24 $915,717 - $915,717	64,306 New	64,306 $0

Others Institutions Holding GRTS

# of Institutions

Shares Held

37.5M

Call Options Held

1.46M

Put Options Held

168K

View Full List

About Gritstone bio, Inc.

Ticker GRTS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 73,006,896
Market Cap $40.2M
Description
Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies against multiple cancer types and infectious diseases. Its lead product candidate is GRANITE, a neoantigen-based immunotherapy for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder ...

More about GRTS

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account